medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2021, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2021; 66 (3)

Brief history of neuromuscular blockers

Martínez REA, Palacios CA, García BM, Acosta RM, Pérez LID, Chávez RMA

Language: Spanish
References: 32
Page: 223-228
PDF size: 276.93 Kb.


ABSTRACT

Neuromuscular blockers play an important role in current anesthesia. Although the paralyzing effect of curare is described in the 1500 with the arrival of settlers to the "new world", the active alkaloids in curare were discovered and used in clinical practice in the early 20th century; it was first used for clinical purposes outside of anesthesia. When the possibility of synthetic production in larger quantities arose, curare and its many successors became part of general anesthesia. Many synthetic compounds were developed and used for clinical practice mainly belonging to the steroidal and benzylisoquinoline derivatives. Each of them with the purpose of creating the "ideal neuromuscular blocker" sunscreen, free of adverse effects, quick-start among other characteristics. There are practically three periods in the history of these compounds: the era of curare (before 1942), the chemical modification of natural species such as succinylcholine (1942-1980) and the actual period (after 1980) with its synthesis from the benzoquinonium and amino steroids.


REFERENCES

  1. Robinson DH, Toledo AH. Historical development of modern anesthesia. J Invest Surg. 2012; 25 (3): 141-149.

  2. Booij HHDJ. The history of neuromuscular blocking agents. Curr Anaesth Crit Care. 2000; 11 (1): 27-33.

  3. Utting JE. The era of relaxant anaesthesia. Br J Anaesth. 1992; 69 (6): 551-553.

  4. Birmingham AT. Fifth W.D.M. Paton memorial lecture. Waterton and Wouralia. Br J Pharmacol. 1999; 126 (8): 1685-1689.

  5. Raghavendra T. Neuromuscular blocking drugs: discovery and development. J R Soc Med. 2002; 95 (7): 363-367.

  6. Bynum WF. Chemical structure and pharmacological action: a chapter in the history of 19th century molecular pharmacology. Bull Hist Med. 1970; 44 (6): 518-538.

  7. Dale HH, Feldberg W, Vogt M. Release of acetylcholine at voluntary motor nerve endings. J Physiol. 1936; 86 (4): 353-380.

  8. King H. Curare alkaloids: 1, tubocurarine. J Chem Soc. 1935. pp. 1381-1389.

  9. Everett BJ, Lowe LA. Wilkinson S. Revision of the structures of (+)-tubocurarine chloride and (+)-chondrocurine. Chem Commun. 1970; 16: 1020-1021.

  10. Valenzuela DM, Stitt TN, DiStefano PS, Rojas E, Mattsson K, Compton DL et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron. 1995; 15 (3): 573-584.

  11. Brown TC, Gebert R, Meretoja OA, Shield LK. Myasthenia gravis in children and its anaesthetic implications. Anaesth Intensive Care. 1990; 18 (4): 466-472.

  12. Kyle RA, Shampo MA. Harold R. Griffith--introduction of muscle relaxants to anesthesia. Mayo Clin Proc. 1992; 67 (3): 237.

  13. Beecher HK, Todd DP. A study of the death associated with anesthesia and surgery. Ann Surg. 1954; 140 (1): 2-34.

  14. Abajian J Jr, Arrowood JG, Barrett RH, Dwyer CS, Eversole UH, Fine JH et al. Critique of "A study of the deaths associated with anesthesia and surgery". Ann Surg. 1955; 142 (1): 138-141.

  15. Beom KY, Sung TY, Seuk YH. Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents. Korean J Anesthesiol. 2017; 70 (5): 500-510.

  16. Inada E, Philbin DM, Machaj V, Moss J, D'Ambra MN, Rosow CE et al. Histamine antagonist and d-tubocurarine-induced hypotension in cardiac surgical patients. Clin Pharmacol Ther. 1986; 40 (5): 575-580.

  17. Stenlake JB, Waigh RD, Urwin J, Dewar GH, Coker GG. Atracurium: conception and inception. Br J Anaesth. 1983; 55 Suppl 1: 3S-10S.

  18. Dorkins HR. Suxamethonium – the development of a modern drug from 1906 to present day. Med Hist. 1982; 26 (2): 145-168.

  19. Brown TCK. Aspects of depolarizing neuromuscular blockers: decamethonium and suxamethonium. Paediatr Anaesth. 2013; 23 (9): 868-870.

  20. Clutton-Brock J. Death following neostigmine. Br Med J. 1949; 1 (4613): 1007.

  21. Baird WL, Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. A pilot study in man. Br J Anaesth. 1967; 39 (10): 775-780.

  22. Savage DS, Sleigh T, Carlyle I. The emergence of NC-45, The emergence of ORG NC45,1-[(2ß,3a,5a,16ß,17ß)-3,17-bis(acetyloxy)-2-(1-piperi-dinyl)-androstan-16-YL]-1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth. 1980; 52 Suppl 1: 3S-9S.

  23. Savarese JJ, Kitz RJ. Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology. 1975; 42 (3): 236-239.

  24. Buckett WR, Hewett CL, Savage DS. Pancuronium bromide and other steroidal neuromuscular blocking agents containing acetylcholine fragments. J Med Chem. 1973; 16 (10): 1116-1124.

  25. Stenlake JB, Waigh RD, Dewar GH. Biodegradable neuromuscular blocking agents. Part 4 Atracurium besylate and related polyalkylene di-esters. Eur J Med Chem. 1981; 16: 515-524.

  26. Foldes F. Rapid tracheal intubation with non-depolarizing neuromuscular blocking drugs: the priming principle. Br J Anaesth. 1984; 56 (6): 663.

  27. Bowman WC, Rodger IW, Houston J, Marshall RJ, McIndewar. Structure: action relationship among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology. 1988; 69 (1): 57-62.

  28. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RP, Sunder N et al. The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U). A short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology. 1988; 68 (5): 723-732.

  29. Meakin G. Dose-response curves for suxamethonium in neonates, infants and children. Br J Anaesth. 1989; 62 (6): 655-658.

  30. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology. 1995; 82 (5): 1139-1145.

  31. Savarese JJ, McGilvra JD, Sunaga H, Belmont MR, Van Ornum SG, Savarad PM et al. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology. 2010; 113 (1): 58-73.

  32. Heerdt PM, Sunaga H, Savarese JJ. Novel neuromuscular blocking drugs and antagonists. Curr Opin Anaesthesiol. 2015; 28 (4): 403-410.




2020     |     www.medigraphic.com